Fleroxacin

DB04576ExperimentalSmall molecule

Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.

Mechanism: The inhibition of DNA gyrase and DNA topoisomerase 2 leads ultimately to cell death as these enzymes are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.
Curator reviewed
Primary indication: Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone.Curator reviewed
Formula / weight: C₁₇H₁₈F₃N₃O₃ · 369.344 g/mol (avg)
Also known as: Fleroxicin
Code names: AM 833 · RO-236240 · RO 23-6240/000

Resolves to

Compound

UNIIN804LDH51KCAS79660-72-3ChEMBLCHEMBL6273ChEBI31810PubChem3357KEGGD01716

Clinical / RWD

RxNorm42322ATCJ01MA08PharmGKBPA164774762

Structure

InChIKeyXBJBPGROQZJDOJ-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN(CCF)C2=C1F)C(O)=O

Targets

P43700gyrAP43702parCP11388TOP2AQ02880TOP2B

What you can answer from here — as of January 29, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

870Drug interactionsStructured to mechanism, not free text

3Marketed productsAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 15 drug categories

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fleroxacin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In